Drug intelligence / Profile preview

BGB-26808

Development stage: Phase 1
Lead developer: BeOne Medicines
Modality: Small Molecules
Administration: Oral

Overview

BGB-26808 is an orally bioavailable small molecule inhibitor targeting hematopoietic progenitor kinase 1 (HPK1; also known as mitogen-activated protein kinase kinase kinase kinase 1, MAP4K1, or MEKKK1). By inhibiting HPK1, a serine/threonine enzyme that acts as an intracellular immunosuppressive regulator constraining T cell activation, BGB-26808 has potential immunostimulating and antineoplastic activities. It is currently under clinical development for the treatment of advanced and metastatic solid tumors. The drug is being evaluated both as monotherapy and in combination with the anti-PD-1 monoclonal antibody tislelizumab[1][2][3][4][5].

Other names: HPK1 inhibitor BGB-26808HPK-1 inhibitor BGB-26808HPK 1 inhibitor BGB-26808

Targets

MAP4K1 (Hematopoietic progenitor kinase 1)

Beyond the preview

Go deeper on BGB-26808.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGB-26808.

Explore the full profile